)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cumberland Pharmaceuticals
Cumberland Pharmaceuticals (CPIX) investor relations material
Cumberland Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Q3 2026 was the first full quarter after the July 1 transaction, which transferred commercial brands and operations to Apotex’s U.S. branded business for $100M at closing.
Strategy shifted to clinical development, prioritizing late-stage programs led by ifetroban and exploring commercialization and partnering alternatives.
Q3 net income of $77.78M included an $81.09M disposal gain; transaction proceeds strengthened liquidity and enabled a $22M special dividend.
Financial highlights
Q3 total revenue was $2.16M, including $1.95M of transition services revenue; operating loss was $1.94M.
Q3 net income was $77.78M, including an $81.09M disposal gain; continuing-operations net loss was $1.12M.
9M 2026 revenue was $2.49M and net income was $70.22M, including the $81.09M disposal gain.
At September 30, cash and equivalents were $80.58M, total assets $113.78M, liabilities $41.60M and equity $72.18M.
Q3 interest income was $0.8M from investment of transaction proceeds.
Outlook and guidance
Ifetroban DMD NDA preparation follows a pre-NDA FDA meeting; rolling review allows completed sections to be submitted ahead of the full filing.
NDA support includes FIGHT DMD and open-label extension data, preclinical and manufacturing information, and a safety database covering over 1,400 subjects across ~30 studies.
Systemic sclerosis plans include filing the clinical study report with FDA and completing biomarker and cardiac imaging analyses to guide further development.
Remaining cash is projected to fund operations for over five years; interim efficacy results are the next IPF trial milestone.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cumberland Pharmaceuticals
- High-dose ifetroban improved DMD LVEF; FDA granted rolling review for a planned NDA.CPIX
Study update - $100M divestiture, special dividend, and clinical pipeline focus drive future growth.CPIXQ2 2026
- Board recommends approval of $100M asset sale to Apotex, enabling a strategic shift to R&D.CPIXProxy filing
- Shareholders to vote on $100M asset sale to Apotex, with board and key holders' strong support.CPIXProxy filing
- $100M Apotex deal and FDA approvals drive pivot to orphan drug pipeline after Q1 growth.CPIXQ1 2026
- Board-approved $100M asset sale to Apotex shifts focus to orphan drug pipeline, pending shareholder vote.CPIXProxy filing
- 2026 meeting covers director elections, auditor ratification, executive pay, and ESG progress.CPIXProxy Filing
- Annual meeting to vote on directors, auditor, executive pay, and say-on-pay frequency.CPIXProxy Filing
- Double-digit revenue growth, improved net loss, and global expansion in 2025.CPIXQ4 2025
Next Cumberland Pharmaceuticals earnings date
Q4 20262 Mar, 2027
Cumberland Pharmaceuticals
Next Cumberland Pharmaceuticals earnings date
Q4 20262 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development, acquisition, and commercialization of prescription medicines. The company's portfolio includes products for hospital acute care, gastroenterology, and rheumatology, addressing the needs of patients in critical care settings. Cumberland Pharmaceuticals is involved in all aspects of the product lifecycle, from clinical research to regulatory approval and distribution. Its target markets include healthcare providers, hospitals, and outpatient facilities across the United States. The company is headquartered in Nashville, Tennessee, and its shares are listed on the NASDAQ.